In a phase II trial (ATLANTIC) evaluating durvalumab in EGFR-/ALK-mutated NSCLC, the ORR was 3.6% in PD-L1 < 25% and 12.2% in PD-L1 ≥ 25% patients [108]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.